Literature DB >> 31187552

Behavioral therapy for urinary symptoms in Parkinson's disease: A randomized clinical trial.

Camille P Vaughan1,2, Kathryn L Burgio3,4, Patricia S Goode3,4, Jorge L Juncos5, Gerald McGwin3,6, Lisa Muirhead1,7, Alayne D Markland3,4, Theodore M Johnson1,2.   

Abstract

AIM: Determine the efficacy of behavioral therapy for urinary symptoms in Parkinson's disease.
METHODS: Randomized trial of behavioral therapy compared with control condition among adults (aged 54-85 years, 74% male, 10% Black/ 83% White) with Parkinson's and greater than or equal to 4 incontinence episodes weekly. Behavioral therapy included pelvic floor muscle exercises, bladder training, fluid and constipation management. Both groups completed bladder diary self-monitoring. Outcomes included diary-derived incontinence and ICIQ-overactive bladder (OAB) score (range, 0-16) with bother and quality of life questionnaires (higher scores = worse outcomes).
RESULTS: Fifty-three participants randomized and 47 reported 8-week outcomes including 26 behavioral therapy and 21 control. Behavioral vs control participants were similar with respect to age (71.0 ± 6.1 vs 69.7 ± 8.2 years), sex (70% vs 78% male), motor score, cognition, mean weekly incontinence episodes (13.9 ± 9.6 vs 15.1 ± 11.1) and OAB symptoms (8.9 ± 2.4 vs 8.3 ± 2.2). Weekly incontinence reduction was similar between behavioral (-6.2 ± 8.7) and control participants (-6.5 ± 13.8) (P = 0.89). After multiple imputation analysis, behavioral therapy participants reported statistically similar reduction in OAB symptoms compared to control (-3.1 ± 2.8 vs -1.9 ± 2.2, P = 0.19); however quality of life (-22.6 ± 19.1 vs -7.0 ± 18.4, P = 0.048) and bother (-12.6 ± 17.2 vs - 6.7 ± 8.8, P = 0.037) improved significantly more with behavioral therapy.
CONCLUSION: Self-monitoring resulted in fewer urinary symptoms; however, only multicomponent behavioral therapy was associated with reduced bother and improved quality of life. Providers should consider behavioral therapy as initial treatment for urinary symptoms in Parkinson's disease.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Parkinson's disease; behavioral therapy; overactive bladder; urinary incontinence

Mesh:

Year:  2019        PMID: 31187552      PMCID: PMC6660386          DOI: 10.1002/nau.24052

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  22 in total

Review 1.  Prediction of institutionalization in the elderly. A systematic review.

Authors:  Melanie Luppa; Tobias Luck; Siegfried Weyerer; Hans-Helmut König; Elmar Brähler; Steffi G Riedel-Heller
Journal:  Age Ageing       Date:  2009-11-23       Impact factor: 10.668

2.  Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.

Authors:  K L Burgio; J L Locher; P S Goode; J M Hardin; B J McDowell; M Dombrowski; D Candib
Journal:  JAMA       Date:  1998-12-16       Impact factor: 56.272

3.  Influence of urinary urgency and other urinary disturbances on falls in Parkinson's disease.

Authors:  Ken Sakushima; Shin Yamazaki; Shingo Fukuma; Yasuaki Hayashino; Ichiro Yabe; Shunichi Fukuhara; Hidenao Sasaki
Journal:  J Neurol Sci       Date:  2015-11-30       Impact factor: 3.181

Review 4.  Lower urinary tract symptoms in Parkinson's disease: Prevalence, aetiology and management.

Authors:  Claire McDonald; Kristian Winge; David J Burn
Journal:  Parkinsonism Relat Disord       Date:  2016-11-01       Impact factor: 4.891

5.  Pilot Results from a Randomized Trial in Men Comparing Alpha-Adrenergic Antagonist versus Behavior and Exercise for Nocturia and Sleep.

Authors:  Theodore M Johnson; Camille P Vaughan; Patricia S Goode; Donald L Bliwise; Alayne D Markland; Carrie Huisingh; David T Redden; Gerald McGwin; Rina Eisenstein; Joseph G Ouslander; Muta Issa; Kathryn L Burgio
Journal:  Clin Ther       Date:  2016-10-28       Impact factor: 3.393

6.  Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study.

Authors:  Uwe Ehrt; Karl Broich; Jan Petter Larsen; Clive Ballard; Dag Aarsland
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-09-21       Impact factor: 10.154

7.  Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease.

Authors:  S Hoops; S Nazem; A D Siderowf; J E Duda; S X Xie; M B Stern; D Weintraub
Journal:  Neurology       Date:  2009-11-24       Impact factor: 9.910

8.  Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients.

Authors:  J A Cooper; H J Sagar; S M Doherty; N Jordan; P Tidswell; E V Sullivan
Journal:  Brain       Date:  1992-12       Impact factor: 13.501

9.  Association of Parkinson's disease with accelerated bone loss, fractures and mortality in older men: the Osteoporotic Fractures in Men (MrOS) study.

Authors:  H A Fink; M A Kuskowski; B C Taylor; J T Schousboe; E S Orwoll; K E Ensrud
Journal:  Osteoporos Int       Date:  2008-02-27       Impact factor: 5.071

10.  Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease.

Authors:  James A G Crispo; Allison W Willis; Dylan P Thibault; Yannick Fortin; Harlen D Hays; Douglas S McNair; Lise M Bjerre; Dafna E Kohen; Santiago Perez-Lloret; Donald R Mattison; Daniel Krewski
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

View more
  4 in total

1.  Exploratory evaluation of baseline cognition as a predictor of perceived benefit in a study of behavioral therapy for urinary incontinence in Parkinson disease.

Authors:  Phat L Chang; Felicia C Goldstein; Kathryn L Burgio; Jorge L Juncos; Gerald McGwin; Lisa Muirhead; Alayne D Markland; Theodore M Johnson; Camille P Vaughan
Journal:  Neurourol Urodyn       Date:  2022-02-19       Impact factor: 2.696

2.  Physical Therapist Management of Parkinson Disease: A Clinical Practice Guideline From the American Physical Therapy Association.

Authors:  Jacqueline A Osborne; Rachel Botkin; Cristina Colon-Semenza; Tamara R DeAngelis; Oscar G Gallardo; Heidi Kosakowski; Justin Martello; Sujata Pradhan; Miriam Rafferty; Janet L Readinger; Abigail L Whitt; Terry D Ellis
Journal:  Phys Ther       Date:  2022-04-01

Review 3.  Autonomic Dysfunction in Parkinson's Disease.

Authors:  Ronald F Pfeiffer
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

4.  Effects of nonsurgical, minimally or noninvasive therapies for urinary incontinence due to neurogenic bladder: a systematic review and meta-analysis.

Authors:  Mohammed Usman Ali; Kenneth Nai-Kuen Fong; Priya Kannan; Umar Muhammad Bello; Georg Kranz
Journal:  Ther Adv Chronic Dis       Date:  2022-03-18       Impact factor: 5.091

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.